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Acutemyeloid leukemia (AML) isdrivenandsustained
by leukemia stem cells (LSCs) with unlimited self-
renewal capacity and resistance to chemotherapy.
Mutation in the TP53 tumor suppressor is relatively
rare in de novo AML; however, p53 can be regulated
through post-translational mechanisms. Here, we
show that p53 activity is inhibited in inv(16)+ AML
LSCs via interactions with the CBFb-SMMHC (CM)
fusion protein and histone deacetylase 8 (HDAC8).
HDAC8 aberrantly deacetylates p53 and promotes
LSC transformation and maintenance. HDAC8 defi-
ciency or inhibition using HDAC8-selective inhibitors
(HDAC8i) effectively restores p53 acetylation and
activity. Importantly, HDAC8 inhibition induces
apoptosis in inv(16)+ AML CD34+ cells, while sparing
the normal hematopoietic stem cells. Furthermore,
in vivo HDAC8i administration profoundly diminishes
AML propagation and abrogates leukemia-initiating
capacity of both murine and patient-derived LSCs.
This study elucidates an HDAC8-mediated p53-inac-
tivatingmechanism promoting LSC activity and high-
lights HDAC8 inhibition as a promising approach to
selectively target inv(16)+ LSCs.
INTRODUCTION
Acute myeloid leukemia (AML) is an aggressive bone marrow
malignancy with over 20,000 new cases and 10,000 deaths
each year in the United States. AML arises from leukemia stem
cell (LSC) transformation as a consequence of multiple cooper-
ative mutations or epigenetic alterations. Recurrent chromo-
somal abnormalities in AML frequently result in transcription
factor fusion proteins that contribute to the unique etiology and
prognosis of distinct cytogenetic subsets (Look, 1997). The
core-binding factor (CBF) complex, consists of a DNA-bindingCellRUNX protein and a non-DNA binding CBFb, is a master tran-
scriptional regulator of hematopoiesis and a frequent target of
leukemia associated mutations (Speck and Gilliland, 2002). A
common recurrent cytogenetic aberration found in approxi-
mately 5%–12% of AML patients is chromosome 16 inversion
inv(16)(p13.1q22) or translocation t(16;16)(p13.1;q22) (hence-
forth inv(16)) (Liu et al., 1996). Inv(16) results in fusion of CBFB
with the MYH11 gene, which encodes a smooth muscle myosin
heavy chain (SMMHC) protein (Liu et al., 1993). The resulting
fusion protein CBFb-SMMHC (CM) retains the RUNX1 binding
interface of CBFb and the coiled-coil rod region of SMMHC.
Heterozygote Cbfb-MYH11 knockin (KI) at the Cbfb locus led
to lethal defects in definitive hematopoiesis at E12.5 (Castilla
et al., 1996), replicating the phenotypes of Runx1- or Cbfb null
mice (Okuda et al., 1996; Wang et al., 1996). These results
suggested that CM is a dominant inhibitor of CBF during he-
matopoietic ontogeny. Our previous studies in a conditional
CM KI mouse model further revealed that CM expression in he-
matopoietic stem cells (HSCs) leads to impaired differentiation
of multiple hematopoietic lineages and produces pre-leukemic
stem and progenitors that are at risk for LSC transformation
(Castilla et al., 1996; Kuo et al., 2006, 2008; Zhao et al., 2007).
However, the molecular mechanism underlying the leukemo-
genic function of CM has been elusive.
AML is maintained and propagated by LSCs that are relatively
resistant to chemotherapy and can persist as potential sources
of relapse. Although patients with inv(16) AML have a relatively
favorable prognosis, only approximately half of them eventually
achieve long-term survival with the standard chemotherapy reg-
imens (Pre´bet et al., 2009; Ustun andMarcucci, 2015). Molecular
insights into leukemogenic mechanisms are necessary to design
new LSC-targeted therapies to reduce relapse and improve
outcomes. TP53 mutations are relatively rare in de novo AML
(approximately 10%); however, TP53 mutation is associated
with complex karyotypes, drug resistance, and dismal outcome
(Ru¨cker et al., 2012; Haferlach et al., 2008). Loss of p53 has also
been shown to promote AML pathogenesis in mice by enabling
aberrant self-renewal (Zhao et al., 2010). The functions of p53
are coordinately modulated by a number of post-translational
modifications including acetylation (Dai and Gu, 2010). GivenStem Cell 17, 597–610, November 5, 2015 ª2015 Elsevier Inc. 597
Figure 1. CM Fusion Protein Binds to p53
and Impairs p53 Acetylation
(A) Western blot time course analysis of Ac-p53,
p53, CM, CBFb, and b-actin after IR (3 Gy) in
CM-expressing or control BM cells.
(B) Western blot time course analysis of Ac-p53,
p53, CM, CBFb, HDAC8, and b-actin after IR (3 Gy)
in 32D-CM or 32D-CBFb cells.
(C) Western blot of Ac-p53, p53, CM, CBFb, and
b-actin in Cbfb56M/+ BM progenitor cells trans-
duced with MIG-Cre and stimulated with IR (3 Gy,
6 hr).
(D) Western blot of Ac-p53, p53, CM, CBFb, and
b-actin in 32D-CM cells expressing control (Ctrl)-
shRNA or CM-shRNA (A3, D4) 6 hr after IR.
(E) Western blot of CM and b-actin (top) and rela-
tive expression of p53 target genes in sorted AML
cells transduced with Ctrl-shRNA or CM-shRNA
(A3, D4) and induced with IR (bottom). Shown in
the image are fold change (mean ± SD) relative to
Ctrl-shRNA-expressing cells, performed in tripli-
cate (*p < 0.05; **p < 0.01; and ***p < 0.001).
(F) CoIP and immunoblot (IB) analysis in 32D-CM
(top) or 32D-CBFb (bottom) cells using anti-p53
or anti-mouse IgG for IP and anti-p53 (left) or anti-
CBFb (right) for IB.
(G) Representative images of Duolink in situ
PLA using mouse anti-CBFb, rabbit anti-p53 anti-
bodies, and PLA probes. The red foci indicate
CM-p53 interactions (left), the DAPI-stained nuclei
are in blue (center), andGFP+ indicates transduced
cells (right). The scale bar represents 10 mm.
(H) CoIP (anti-CBFb) and IB (anti-p53 or anti-CBFb)
analysis in control BM or CM BM cells with or
without IR (3 Gy).
(I) CoIP (anti-p53 or IgG) and IB (anti-CBFb or
anti-p53) in inv(16)+ AML (163, 987) or non-inv(16)
AML (467, 865) CD34+ cells 3 hr after IR.
See also Figure S1.the low TP53 mutation rate, alternative mechanisms affecting
p53 protein stability or post-translational modification are
possibly involved in disrupting p53 function during AML
pathogenesis.
Histone deacetylases (HDACs) are a family of enzymes that
catalyze the removal of acetyl moieties from lysine residues in
a variety of histones proteins and transcription factors including
p53. HDAC8 is a class I HDAC that is overexpressed in multiple
tumor types, including neuroblastoma, glioma (Oehme et al.,
2009), and childhood acute lymphoblastic leukemia (Moreno
et al., 2010). Although HDAC8 has been shown to interact with
the CM chimeric protein as part of a transcriptional repressor
complex (Durst et al., 2003), its functional role in AML pathogen-
esis is unclear. In this study, we uncovered an HDAC8-mediated
post-translational p53-inactivating mechanism underlying CM-
associated LSC transformation and maintenance. We inves-
tigated the functional contribution of HDAC8 in human AML
stem/progenitor cell survival and propagation and evaluated
the efficacy of HDAC8-selective inhibitors in targeting murine
and human AML LSCs in vivo.598 Cell Stem Cell 17, 597–610, November 5, 2015 ª2015 Elsevier InRESULTS
CM Fusion Protein Binds to p53 and Impairs
p53 Acetylation
The activity of p53 is normally tightly controlled and is rapidly
induced upon genotoxic stress triggered by radiation or chemo-
therapy. Acetylation of the p53 protein, critical for its stability and
transcriptional activity, is rapidly induced upon p53 activation
(Dai and Gu, 2010). We have previously generated a conditional
CM KI mouse model (Cbfb56M/+/Mx1-Cre), which expresses
CM under the endogenous Cbfb promoter after polyinosinic
polycytidylic acid (pIpC) treatment (Kuo et al., 2006). Western
blot analysis using an antibody against an acetylated (Ac)-form
of p53 (K379) revealed that Ac-p53 levels were largely reduced
in CM pre-leukemic (2 weeks after pIpC) bone marrow (BM) cells
treated with g-irradiation (IR, 3Gy) compared to similarly treated
control BM (Figure 1A). Time course analysis revealed that the
initial acetylation of p53 occurred (2 hr), however, p53was rapidly
deacetylated in the presence of CM (Figure 1A). To verifywhether
this is directly related toCMexpression,we transducedamyeloidc.
progenitor cell line 32D (p53 intact) with MSCV-ires-GFP (MIG)
expressing FLAG-tagged CM (32D-CM) or normal CBFb (32D-
CBFb). The levels of Ac-p53 were consistently reduced in 32D-
CMcompared to 32D-CBFb cells (Figure 1B). In addition, expres-
sion of CM by transducing Cbfb56M/+ BM cells with a MIG-Cre
vector readily reduced Ac-p53 induction (Figure 1C), suggesting
that this is likely to be a direct effect of CM. Furthermore, knock-
ing down CM using small hairpin (sh)-RNAs against the Cbfb-
MYH11 sequence rapidly restored Ac-p53 induction in 32D-CM
cells (Figure 1D). Similarly, silencing CM in mouse AML cells
significantly induced p53 target gene expression (Figures 1E
and S1A). The transcription of p53 was not affected as CM
expression in 32D cells or in primary myeloid progenitors did
not cause significant changes in p53mRNA levels (Figure S1B).
To determine how CM fusion protein impairs p53 activity, we
examined whether CM interacts with the p53 protein. First, we
performed coimmunoprecipitation (coIP) followed by western
blot analysis in 32D-CM and 32D-CBFb cells. We found that
the CM fusion protein, but not CBFb, was pulled down together
with p53 (Figures 1F and S1D). As an alternative approach, we
used a proximity ligation assay (PLA) to assess intermolecular
interaction in situ. Punctate red fluorescent foci were observed
in 32D-CM, but not 32D-CBFb cells (Figure 1G), indicating the
presence of specific interaction between CM and p53 proteins.
In contrast, in situ PLA using an Ac-p53 (K379) specific antibody
showed very few interacting foci (Figure S1C), suggesting that
the p53 protein interacting with CM is mostly deacetylated. Nu-
clear and cytoplasmic fractionation revealed that the CM-p53
complex is detected mainly in the nucleus (Figure S1E). Similar
CM-p53 interaction was seen when RUNX1 is knocked down
(Figure S1F), suggesting that RUNX1 is not required for CM-
p53 binding. The CM-p53 complex can also be detected in
primary CMpre-leukemic BM cells with or without IR (Figure 1H).
Furthermore, coIP in primary AML CD34+ cells isolated from
patients showed that CM-p53 protein complex was seen specif-
ically in inv(16)+ AML CD34+ cells and not in non-inv(16) cells
(Figure 1I). Altogether, these results indicate that CM fusion pro-
tein binds to p53 and impairs acetylation and activation of p53.
HDAC8 Mediates CM-Induced Deacetylation of p53
Consistent with a previous report (Durst et al., 2003), we found
that CM interacts specifically with HDAC8 and not other class I
HDACs including HDAC1, HDAC2, or HDAC3 (Figures S2A and
S2B). We next assessed whether CM forms a multimeric protein
complex with HDAC8 and p53 by sequential IP followed bywest-
ern blot analysis. Indeed, we were able to pull down CM, p53,
and HDAC8 in a protein complex using two different antibody
sequential combinations (Figure 2A). To further examine whether
the CM-p53 interaction is dependent on HDAC8 binding, we
generated a set of CM deletion mutants (Figure 2B, left). The
CM-DC95 mutant lacking 95 amino acids at the C terminus did
not bind HDAC8 (Figure S2B), as previously reported (Durst
et al., 2003). CoIP and in situ PLA revealed that CM-DC95 can
bind p53, while CM variants d134 (residues 134–236 deleted)
and d179 (residues 179–221 deleted) cannot (Figures 2B and
2C). In addition, coIP and in situ PLA showed that CM-p53 bind-
ing was unaffected in Hdac8 knocked down 32D-CM cells
(Figures 2C, 2D, and S2C). These results suggest that CM-p53
interaction does not require HDAC8 binding. However, aberrantCellp53 deacetylation associated with CM depends critically on
Hdac8 because knocking down Hdac8 led to a robust increase
in Ac-p53 induced by IR (Figure 2E). In addition, CM deletion
mutants DC95, d134, or d179 that were unable to bind either
HDAC8 or p53 had no effect on Ac-p53 induction compared to
control (FLAG or CBFb) 32D cells (Figures 2F and S2D). Quanti-
tative (q) RT-PCR analysis shows that induction of p53 target
genes including p21 Cdkn1a, Mdm2, Bid, Bax, and Gadd45b
were restored in CM-DC95 cells compared to full-length CM-
expressing cells (Figure 2G). Collectively, these results indicate
that although binding to p53 and HDAC8 occurs through
distinct regions of the CM protein, simultaneous interaction
with HDAC8 and p53 is required for aberrant deacetylation and
inactivation of p53.
HDAC8 Promotes CM-Induced LSC Transformation
and Cell Survival through Deacetylase Activity
To determine the contribution of HDAC8 in CM-induced AML
LSC transformation, we generated a floxed Hdac8 (Hdac8f)
allele in which exon 3 was flanked by loxP sites (Figure S3A).
Mice carrying Hdac8f/f were crossed with Cbfb56M/+/Mx1-Cre
(C56Bl6 strain) and induced with pIpC as previously described
(Kuo et al., 2006). Successful induction of Hdac8 deletion
in Hdac8KO/Cbfb56M/+/Mx1-Cre mice was confirmed by PCR
(data not shown) and western blot analysis (Figure 3A). CM/
Hdac8KO pre-leukemic BM progenitors show significantly higher
levels of Ac-p53 upon IR (Figures 3B and S3B), consistent with
HDAC8 mediating CM-associated p53 deacetylation. Similar
to previous studies, C56BL/6 CM KI mice spontaneously
develop AML with 100% penetrance and a median survival of
122 days. Notably, deletion ofHdac8 (CM/Hdac8KO) significantly
(p < 0.0001) reduced AML incidence (13.6%) and prolonged
disease-free survival (Figure 3C). These results indicate that
HDAC8 promotes LSC transformation and AML progression.
To test whether p53 acetylation and activity could be modu-
lated by HDAC8 deacetylase activity, we used HDAC8-selective
pharmacological inhibitors (HDAC8i) including PCI-34051 (Bala-
subramanian et al., 2008) and compound 22d (Huang et al.,
2012) designed to block HDAC8 catalytic activity. Treatment
with both HDAC8i compounds remarkably enhanced Ac-p53 in
32D-CM cells (Figure 3D, lanes 3, 8, and 9 from left). Because
p53 protein levels were also increased upon HDAC8i treatment,
we included the Mdm2 inhibitor Nutlin-3 to stabilize the p53 pro-
tein. Treatment of HDAC8i (PCI-34051 or 22d) in combination
with Nutlin-3 elevated Ac-p53 compared to Nutlin-3 alone (Fig-
ure 3D, lanes 4–6 and 10–12 from left), suggesting that the
enhanced Ac-p53 by HDAC8i is not a result of p53 protein stabi-
lization. In fact, 22d differentially increased Ac-p53 as well as the
HDAC8-specific substrate Ac-SMC3 (Deardorff et al., 2012)
compared to other class I HDAC (MS-275), class III HDAC
(TV6), or broad-spectrum (PCI-24781) inhibitors with limited
HDAC8 inhibitory activity (Figures 3E and S3C). In addition,
HDAC8i (PCI-34051 or 22d) treatment significantly induced
expression of multiple p53 targets as determined by qRT-PCR
analysis (Figure 3F). This is indeed p53-dependent, since knock-
ing down p53 significantly reduced the effect (Figures S3D and
S3E). Similarly, Hdac8 deletion significantly decreased p53
targets induction by 22d (Figure 3G). Activation of p53 upon
22d treatment was accompanied by a dose-dependent increaseStem Cell 17, 597–610, November 5, 2015 ª2015 Elsevier Inc. 599
Figure 2. CM Fusion Protein Recruits HDAC8 and p53 in a Protein Complex and Promotes the Deacetylation of p53 by HDAC8
(A) Sequential coIP (1 IP anti-HDAC8 or anti-p53 and 2 IP anti-CBFb) and IB (anti-p53 or anti-HDAC8) analysis in 32D-CBFb or CM cells that were not IR (left) or
IR (3 Gy) treated (right).
(B) Illustration of CM deletion variants (left) used in the coIP (anti-p53) and IB (anti-CBFb or anti-p53) analysis (right). The red arrows indicate the expected size of
CM variants.
(C) Representative images of in situ PLA in 32D FL-CM, d134, d179, DC95, Ctrl-, or Hdac8-shRNA (sh1 or sh2) expressing cells using mouse anti-CBFb, rabbit
anti-p53, and PLA probes. The CM-p53 interactions are shown in red (top), the DAPI staining are in blue (center), and the GFP reporter indicates transduced cells
(bottom). The scale bar represents 10 mm.
(legend continued on next page)
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Figure 3. Hdac8 Deletion Diminishes CM-
Induced LSC Transformation and Promotes
p53 Activation
(A) Western blot analysis of Hdac8, CM, and CBFb
in BM cells from Cbfb56M/+/Mx1-Cre (CM) or CM/
Hdac8KO mice 2 weeks after seven doses of pIpC
treatment.
(B) Western blotting of Ac-p53 or p53 in pre-
leukemic CM or CM/Hdac8KO BM cells before or
2 hr after IR (3 Gy).
(C) Kaplan-Meier survival curve of induced CM
(n = 23; median survival 122 days) or CM/Hdac8KO
mice (n = 56) monitored up to 1 year.
(D) Western blotting of Ac-p53, p53, Hdac8, and
b-actin in 32D-CM cells treated with indicated
dose of HDAC8i PCI-34051 (mM), 22d (mM), or
Nutlin-3 (2.5 mM) for 6 hr.
(E) Western blotting of Ac-p53, p53, Ac-Smc3,
Smc3, and b-actin in 32D-CM cells treated with
22d (5 mM), MS-275 (2.5 mM), TV6 (2.5 mM), PCI-
24781 (200 nM), or Nutlin-3 (2.5 mM).
(F) Fold activation of p53 targets in 32D-CM cells
treated with HDAC8i PCI-34051 (10 mM) or 22d
(10 mM) for 16 hr, relative to levels in vehicle treated
cells (dashed line). Shown in the image are the
mean ± SD of triplicated qRT-PCR assays and two
experiments.
(G) Fold activation of p53 targets in primary CM
(n = 4) or CM/Hdac8KO (n = 5) progenitors cells
treated with the HDAC8i 22d (10 mM) for 16 hr,
relative to levels in vehicle treated cells (dashed
line). The mean ± SD of triplicated qRT-PCR
assays are shown in the image.
(H) Survival inhibition dose-response curve and
IC50 of HDAC8i 22d for 32D-CBFb, 32D-CM, or
32D-CM cells overexpressing HDAC8.
(I) Western blot analysis of Ac-p53, p53, Ac-SMC3,
SMC3, HDAC8, and b-actin in 32D-CM cells with
or without HDAC8 overexpression (O/E) treated
with 22d (0, 2.5, 5, and 10 mM).
(J) Fold induction of luciferase reporter under the
control of p53 responsive elements in K562 cells
cotransfected with CM and p53-WT or p53-8KR
mutant and treated with 22d (10 mM). The dashed
line indicates levels in vehicle treated cells. The
mean ± SD of four assays in two experiments are
shown (*p < 0.05; **p < 0.01; and ***p < 0.001).
See also Figure S3.in apoptosis of 32D-CM cells (IC50 = 4.25 mM) compared to 32D-
CBFb cells (IC50 = 7.54 mM). This enhanced apoptosis and Ac-
p53 can be rescued by overexpression of HDAC8 (IC50 =
9.15 mM; Figures 3H and 3I). In addition, primary CM/Hdac8KO
BM cells (IC50 = 7.36 mM) were significantly more resistant
to 22d-induced apoptosis compared to CM BM cells (IC50 =
4.99 mM; Figure S3F). To further substantiate that this is
mediated by p53 activation, we expressed CM in BM cells
from p53ERTAM KI mice carrying a 4-hydroytamoxifen (4-OHT)
inducible form of the p53 protein (Christophorou et al., 2005).(D) CoIP (IgG or anti-p53) and IB (anti-CBFb or anti-p53) in 32D-CM cells expres
(E) Western blotting of Hdac8, Ac-p53 (K379), p53, and b-actin in 32D-CM cells
(F) Western blotting of Ac-p53, p53 in CM-, DC95-, CBFb-, or FLAG-expressing
(G) Fold induction of p53 target genes in CBFb-, CM-, or CM-DC95-expressing
and two experiments (*p < 0.05; **p < 0.01; and ***p < 0.001).
See also Figure S2.
CellRestoring p53 activity upon 4-OHT treatment significantly
increased apoptosis and the sensitivity to 22d (Figure S3G).
Furthermore, human K562 cells (p53 inactive) were significantly
(p = 0.0024) more sensitive to 22d when coexpressing CM and
wild-type (WT) p53 (IC50 = 9.48 mM) compared to an acetylation
sites-mutated (8KR; IC50 = 21.03 mM) form of p53 (Figures S3H
and S3I). Using a p53-luciferase reporter construct under the
control of p53 responsive elements (Dai et al., 2004), we show
that p53 transcription activity is significantly induced by 22d in
K562 cells rescued with p53-WT, but not p53-8KR (Figure 3J).sing Ctrl- or Hdac8-shRNA (sh1 or sh2).
expressing Ctrl- or Hdac8-shRNA after IR (3 Gy, 6 hr).
32D cells before or after IR (3 Gy).
cells, 24 hr after 3 Gy IR. The bars represent mean ± SD duplicated assays
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Figure 4. Inhibition of HDAC8 Selectively In-
duces p53-Dependent Apoptosis in Inv(16)+
AML Stem/Progenitor Cells
(A) Relative expression of HDAC8 in NL PBSC
(n = 7; mean indicated by dashed line), inv(16)+
AML (n = 7), or non-inv(16)+ AML (n = 19) CD34+
cells. Each dot represents the average of triplicate
qRT-PCR assays from an individual patient and the
line indicates the mean ± SEM of all the samples.
(B) Percent survival of NL (n = 7), inv(16)+ AML
(n = 12), t(8;21) AML (n = 3), or other non-inv(16)
AML (n = 4) CD34+ cells treated with HDAC8i 22d
for 48 hr, measured by Annexin V labeling. Each
dot represents an individual subject and the lines
indicate the mean ± SEM.
(C) Survival inhibition dose-response curve and
IC50 of HDAC8i 22d for NL, inv(16)
+ AML, t(8;21)
AML, or other non-inv(16) AML CD34+ cells as
described in (B).
(D)Westernblots ofAc-p53 (K382), p53, andb-actin
in inv(16)+ AML CD34+ cells treated with 22d
(10 mM) or Nutlin-3 (2.5 mM) for 6 hr. Shown in the
image are representative results from four patients.
(E) Fold induction of p53 target genes in inv(16)+
AML CD34+ (n = 9–13) or NL CD34+ (n = 7) cells
treated with 22d (10 mM) for 16 hr, relative to the
levels in vehicle treated cells (dashed line). Each
dot represents the mean of triplicated qRT-PCR
assays for an individual subject and the lines
indicate the mean ± SEM.
(F) Representative fluorescence-activated cell
sorting (FACS) plot of Annexin V/DAPI labeling in
inv(16)+ AML CD34+ cells expressing control (ctrl)
or p53 shRNA (GFP+) and treatedwith 22d for 48 hr.
(G) Relative survival of sorted GFP+ inv(16)+ AML
CD34+ cells expressing ctrl- or p53-shRNA treated
with 22d for 48 hr (top). Each dot represents an
individual patient and the lines indicate mean ±
SEM. The dose-response curve and IC50 of shctrl-
(solid line) or shp53-cells (dashed line) treated with
22d (bottom).
(H) Percent survival of inv(16)+ AML (n = 3–7)
CD34+ cells treated with 22d (5 or 10 mM)
or combined with DNR (50 or 100 nM) or Ara-C
(0.2, 1, and 5 mM) (*p < 0.05; **p < 0.01; and ***p <
0.001; not significant: ns).
See also Figure S4 and Table S1.Altogether, these results provide genetic evidence that 22d in-
duces p53 activation and apoptosis through inhibition of HDAC8.
Inhibition of HDAC8 Selectively Induces Apoptosis
of Human Inv(16)+ AML Stem and Progenitor Cells
To evaluate the role of HDAC8 in human AML, we first examined
the expression of HDAC8 in primary human CD34+ cells. The
levels of HDAC8 mRNA were significantly higher in inv(16)+
AML CD34+ cells (n = 7; p = 0.0003) compared to normal (NL)
mobilized CD34+ peripheral blood stem cells (PBSCs; n = 7) or
non-inv(16) AML (n = 19) CD34+ cells (Figure 4A). Treatment
with HDAC8i (22d, 48 hr) significantly reduced the proliferation
of inv(16)+ CD34+ cells relative to NL CD34+ cells (Figure S4A;
inv(16)+ AML n = 9; NL n = 7). More importantly, 22d selectively
induced apoptosis of inv(16)+ AML CD34+ cells (IC50 = 10.65 mM)
compared to t(8;21)+ CBF AML (IC50 = 25.99 mM; p = 0.0176),
other non-inv(16) AML CD34+ (IC50 = 45.56 mM; p = 0.0011) or602 Cell Stem Cell 17, 597–610, November 5, 2015 ª2015 Elsevier InNL CD34+ (IC50 = 99.92 mM; p < 0.0001) cells (Figures 4B and
4C). Meanwhile, treatment with 22d (10 mM) did not affect the
short- or long-term engraftment capacity of NL CD34+ cells (Fig-
ure S4B and data not shown).
Next, we assessed whether HDAC8i could selectively activate
p53 in inv(16)+ AML CD34+ cells. Indeed, enhanced Ac-p53
(K382) upon 22d (6 hr) treatment were consistently observed
in all inv(16)+ patient samples, but not in non-inv(16) AML
(p53 non-mutated) or NL CD34+ cells (Figures 4D and S4C and
data not shown). Expression of p53 target genes, particularly
apoptosis-related genes, were also significantly induced in
inv(16)+ CD34+ cells (n = 9–13) relative to NL (n = 7) CD34+ cells
(Figure 4E). The apoptosis-inducing effect of 22d was signifi-
cantly reduced in p53 knocked down (Figure S4D) inv(16)+
CD34+ cells (IC50 = 54.6 mM; p = 0.0079) compared to non-
silenced control (IC50 = 16.62 mM) (Figures 4F and 4G; n = 5),
suggesting that p53 is critical for the apoptotic effects of 22d.c.
Figure 5. Ex Vivo Treatment of HDAC8i 22d Diminishes AML Engraftment and Leukemia Initiation
(A) Schematic illustration of the experimental design. The AML cells were isolated from pIpC-induced Cbfb+/56MMx1Cre/tdTomato+moribund mice, treated with
22d or vehicle for 48 or 72 hr, and transplanted into congenic mice. The engraftment of AML in PB was monitored over time (4 and 8 weeks). The mice were
analyzed for BM and spleen engraftment at 8 weeks or monitored for leukemia onset and survival up to 8 months.
(B) Engraftment of AML cells in the PB at 4 (n = 7) (p = 0.0006) or 8 weeks (vehicle, n = 5 and 22d, n = 7) (p = 0.0025). Shown in the image are mean ± SEM.
(C) Representative images of spleens from recipients of vehicle treated (top) or 22d treated cells (bottom) at 8 weeks.
(D) Representative FACS plots and frequencies of engrafted dTomato+/cKit+ AML cells in the BM at 8 weeks.
(E) Frequency of AML cells in the BMof recipients of vehicle treated (n = 5) or 22d treated cells (n = 7). Each dot represents results from an individual mouse and the
lines indicate mean ± SEM (**p = 0.0025).
(F) Frequency of AML cells in the spleen of recipients of vehicle treated (n = 5) or 22d treated cells (n = 7) (**p = 0.0025).
(G) Survival curve of mice transplanted with AML cells treated with 22d (n = 8) or vehicle (n = 11) (***p = 0.0007).
(H) The frequency of dTomato+ cells in the PB 8 weeks after transplantation of 23 106 live AML cells treated with 22d or vehicle ex vivo for 48 hr (n = 4). Each dot
represents results from individual mice and the lines indicate mean ± SEM (*p = 0.0357).
(legend continued on next page)
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Furthermore, treatment with 22d (5 or 10 mM) significantly
enhanced the sensitivity to cytarabine (Ara-C) or daunorubicin
(DNR), commonly used chemotherapeutics for AML treatment
(Figure 4H). These results suggest that inv(16)+ AML stem and
prognitors are selectively dependent on HDAC8 activity for sur-
vival and that inhibiting HDAC8 activates p53, thereby sensitizing
for apoptosis.
Pharmacologic Inhibition of HDAC8 Abrogates AML
Propagation and Eliminates LSC Leukemia-Initiating
Capacity
AML LSCs are functionally defined by their capacity to engraft
and reproduce AML disease in serial transplants. To test whether
HDAC8 inhibition could affect AML engraftment and LSC leuke-
mia-initiating capacity, we used a CM AML mouse model with a
tdTomato+ Cre-reporter (Cbfb56M/+/Mx1-Cre/tdTomato+). These
mice develop transplantable AML 3–6 months after pIpC induc-
tion and allow easy tracking of CM-expressing AML cells
(dTomato+/cKit+). First, we examined the effect of 22d treatment
on AML cell engraftment capacity after ex vivo exposure (Fig-
ure 5A). AML engraftment was clearly inhibited by 22d treatment,
as evidenced by low amounts of AML cells detected in the
peripheral blood (PB), spleen, and BM of mice receiving 22d
treated cells (Figures 5B–5F, S5A, and S5B). Over 80% (nine of
11) of vehicle treated recipients succumbed to lethal AML
(median survival 68 days), while no AML reoccurrence was
observed in 22d treated group (n = 8) monitored up to 8 months
(Figure 5G; p = 0.0007). In addition, we assessed changes in the
engraftment capacity of AML cells by transplanting equal
numbers of cells (2 3 106) that survived the 22d or vehicle treat-
ment (48 hr). Similarly, engraftment levels were significantly
lower in recipients of 22d treated cells compared to the vehicle
control group in which two mice died of aggressive AML before
analysis (Figures 5H, 5I, S5C, and S5D). None of the 22d treated
recipients developed leukemia compared to lethal AML seen in
100% (n = 4) of the vehicle control mice (Figure 5J; p =
0.0091). These results indicate that HDAC8i treatment dimin-
ished AML engraftment capacity on a per cell basis.
Next, we evaluated the efficacy of in vivo administration
of HDAC8i 22d. To generate cohorts of AML-bearing mice,
AML cells were directly transplanted into sublethally irradiated
(6.5 Gy) congenic recipients. After 5–6 weeks, AML-bearing
mice were treated with vehicle or 22d by intraperitoneal injection
(50 mg/kg/dose) twice a day for 2 weeks (Figure 6A). We found
that Ac-p53 and Ac-SMC3 levels were effectively induced as
early as 2 days after initiating 22d treatment (Figure 6B). Post-
treatment analysis revealed a significantly reduced frequency
(p = 0.0097) and number (p = 0.0101) of dTomato+/cKit+ AML
cells in the BM and spleen of 22d treated compared to vehicle
treated mice (Figures 6C–6E and data not shown). To further
assess LSC activity, we transplanted BM cells (2 3 106) from
these treated mice into secondary recipients. A significantly
reduced frequency (p < 0.0001) and number (p = 0.0006) of
dTomato+/cKit+ AML cells were observed in the BM at 8 weeks(I) The frequency of dTomato+/ckit+ cells in the BM 28 weeks after transplantatio
died of AML prior to analysis) ex vivo for 48 hr (n = 4). Each dot represents resul
(J) Survival curve of mice transplanted with 2 3 106 live AML cells treated with 2
See also Figure S5.
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weight and AML infiltration (Figure 6H and data not shown).
Wemonitored leukemia onset and survival in a cohort of second-
ary recipients who received BM cells (5 3 106) from 22d
or vehicle treated mice. While all vehicle treated transplants
(n = 5) succumbed to aggressive AML with a median survival
of 51 days, only two (of four) 22d treated transplants showed
signs of leukemia with prolonged latency (median survival
270 days; Figure 6I). Collectively, these results indicate that
in vivo 22d treatment effectively diminishes AML burden and
eliminates the leukemia-initiating capacity of LSCs in CM AML
mouse model.
To further evaluate the efficacy of targeting human AML LSCs,
we expanded primary patient-derived inv(16)+ AML cells in NOD/
SCID/IL-2R-g//Tg (CMV-IL3, CSF2, KITLG) mice (NSGS).
T cell depleted AML cells (13 106) were transplanted into irradi-
ated (300 cGy) NSGS mice via intrafemoral injection. Human
AML (hCD45+) cells were selected from leukemic BM for trans-
plantation into larger cohorts. When levels of hCD45+ AML cells
reached 5%–6% in sampled BM aspirates (Figure S6A), we
began treatment with 22d or vehicle twice daily for 2 weeks (Fig-
ure 7A). Two of the six vehicle treated mice were moribund with
aggressive leukemia before the end of treatment, while all 22d
treated mice (n = 5) survived. AML burden indicated by the
frequency and numbers of hCD45+ AML cells and hCD45+/
CD34+ AML stem/progenitor cells were significantly lowered in
BM, PB, and spleen of 22d treated compared to vehicle treated
mice (Figures 7B–7F, S6B, and S6C). No significant change in
immunophenotype was seen for the remaining hCD45+ cells
(Figures S6D and S6E). We further assessed the effects
on LSC leukemia-initiating activity by transplanting BM cells
(4 3 106) from 22d or vehicle treated mice. While significant
AML burden (29%–41% hCD45+; 19.5%–26.8% hCD45+/
CD34+) was observed in vehicle control transplants at 12 weeks,
we found only minimal residual hCD45+ cells (0.63%–1.08%)
and hCD45+/CD34+ AML stem/progenitor cells (0.28%–0.46%)
in 22d treated secondary transplants (Figures 7G–7I and S6F–
S6I). The frequencies of primitive CD34+ population within re-
maining hCD45+ cells were significantly reduced in recipients
of 22d treated BM (Figure 7J), suggesting a selective loss of
AML stem/progenitor cells. In line with a depletion of AML
LSCs by HDAC8i, we did not find any reoccurrence of AML
in 22d treated secondary transplants compared to lethal re-
growth of AML (median survival 93 days) in all vehicle treated
transplants (Figure 7K). Altogether, these results provide
compelling evidence that in vivo administration of HDAC8i
22d profoundly abrogates AML propagation and eliminates
long-term maintenance of functional LSCs.
DISCUSSION
In this study, we delineate a leukemogenic mechanism
whereby the CM fusion protein disrupts p53 activity through
aberrant post-translational modification mediated by HDAC8.n of 23 106 live cells treated with 22d (n = 4) or vehicle (n = 2; another two had
ts from individual mice and the lines indicate mean ± SEM (*p = 0.0206).
2d or vehicle (n = 4) (**p = 0.0091).
c.
Figure 6. Administration of HDAC8i 22d In Vivo Effectively Reduces AML Burden and Abrogates LSC Activity
(A) Schematic illustration of the experimental design. The CM/tdTomato+ AML cells (23 106) were transplanted into cohorts of congenic mice. After 5–6 weeks,
the mice were treated with vehicle or 22d (50 mg/kg/dose) twice a day for 2 weeks. The AML engraftment was analyzed at the end of the treatment and
BM cells were transplanted into second recipients, which were analyzed for engraftment at 8 weeks or monitored for leukemia onset and survival monitored up to
1 year.
(B) Western blot analysis of Ac-p53, Ac-SMC3 levels in BM cells from mice treated with HDAC8i 22d, or vehicle.
(C) Representative FACS plots showing gating and frequency of dTomato+/cKit+ AML cells in the BM of vehicle (top) or 22d treated mice (bottom).
(D) Frequency of AML cells in the BMof mice treated with vehicle (n = 13) or 22d (n = 13) for 2 weeks. Each dot represents results from an individual mouse and the
lines indicate mean ± SEM (**p = 0.0097).
(E) Total number of AML cells in the BM of mice treated with vehicle (n = 13) or 22d (n = 13) for 2 weeks (*p = 0.01).
(legend continued on next page)
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We demonstrate that genetic deletion of Hdac8 or inhibition of
HDAC8 activity drastically prevented LSC transformation and
maintenance. These studies indicate that HDAC8 is a valuable
target for further therapeutic development in inv(16)+ AML and
potentially other HDAC8-overexpressing cancers.
The molecular basis of CM’s leukemogenic activity has been
debated over the years. Dominant inhibition of RUNX proteins
by CM, either through cytoplasmic sequestration (Adya et al.,
1998; Kanno et al., 1998) or constitutive repression (Lutterbach
et al., 1999; Durst et al., 2003), was conventionally viewed as
the main leukemogenic mechanism. However, several recent
studies revealed that CM-induced leukemogenesis in fact re-
quires functional RUNX proteins rather than RUNX inhibition.
First, we showed that high Runx2 expression facilitates CM-
induced AML transformation (Kuo et al., 2009). Second, the
high-affinity RUNX1 binding site presumably underlying domi-
nant RUNX inhibition (Lukasik et al., 2002) seemed dispensable
for CM-leukemogenesis (Kamikubo et al., 2010). Third, RUNX1
activity was reported required for CM leukemogenesis and
growth of CBF AML cells (Hyde et al., 2015; Ben-Ami et al.,
2013; Goyama et al., 2013). Here, we propose a model that
HDAC8-mediated deacetylation of p53 is a major mechanism
contributing to CM-leukemogenesis. Although RUNX1 is not
required for CM-p53 interaction, RUNX-binding could possibly
facilitate localization of CM in the nucleus where CM-p53 inter-
action is detected. The C-terminal deletion mutant CM-DC95
does not bind HDAC8 or impair p53 response, consistent with
its lack of leukemogenic activity (Kamikubo et al., 2012). We
found that CM residues 179–221, located at the SMMHC fusion
junction, are required for binding to p53. This region may
contribute to direct p53 binding or the unique conformational
properties of the CM fusion protein. Overall, our study highlights
that the CM fusion protein gains additional leukemogenic func-
tions beyond its role in RUNX inhibition.
We found that HDAC8 mRNA expression is selectively higher
(5- to 12-fold) in inv(16)+ CD34+ AML cells compared to non-
inv(16) AML or NL CD34+ cells. Overall, non-inv(16) AML
CD34+ cells also express higher levels (2- to 3-fold on average)
of HDAC8 compared to NL CD34+ cells. This could possibly
explain the higher sensitivity to HDAC8i 22d observed for non-
inv(16) AML CD34+ relative to NL CD34+. The mechanism under-
lying this activity needs to be further defined, but these results
raise the possibility that HDAC8i might be applicable to addi-
tional subsets of AML patients. It is not surprising that t(8;21)+
AML is also somewhat sensitive to HDAC8i, given that the
RUNX1-ETO fusion protein is known to interact with repressor
complexes and HDACs (Amann et al., 2001). In fact, anti-leuke-
mia activities in t(8;21)+ AML have been described for class I
HDAC inhibitors (Yang et al., 2007; Odenike et al., 2008; Bots
et al., 2014). In inv(16)+ AML, the HDAC8 level is approximately
2-fold higher in CD34+ population relative to CD34 cells in
each patient (Figure S4E). However, no significant correlation
was seen between HDAC8 levels and sensitivity to HDAC8i
22d (Figure S4F). We also did not observe any difference in(F) Frequency of AML cells in the BM of secondary transplant recipients of BM fr
(G) Total number of AML cells in the BM of second transplant recipients of vehic
(H) Spleen weight of second transplant recipients of vehicle (n = 5) or 22d treate
(I) Survival curve of second transplant recipients of vehicle (n = 5) or 22d treated
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as c-KIT mutation (Figure S4G). Our results suggest that given
the CM-p53-HDAC8 protein complex, inv(16)+ cells are particu-
larly sensitive to HDAC8i regardless of HDAC8 levels. Notably,
HDAC8i treatment enhances the chemosensitivity of inv(16)+
CD34+ cells, highlighting its potential efficacy in overcoming
chemotherapy resistance. Importantly, the apoptotic effect of
HDAC8i is selective for LSCs compared to NL HSCs, which
display little increase in p53 activity and normal engraftment ca-
pacity after HDAC8i treatment. This selectivity is likely due to the
combination of oncogenic stress and the recruitment of HDAC8
and p53 into a stable protein complex in inv(16)+ cells. HDAC8
was recently shown to repress Runx2 activity and osteogenic
differentiation (Fu et al., 2014). Therefore, additional microenvi-
ronmental factors could possibly contribute to the in vivo func-
tional effects of HDAC8i.
Given that TP53 is rarely mutated in inv(16)+ AML, our results
not only elucidate an alternative oncogenic lesion-specific p53-
inactivating mechanism, but also highlight a unique therapeutic
opportunity to selectively modulate p53 activity in inv(16)+
AML. Inhibition of MDM2 by Nutlins or other inhibitors has
been explored as an approach to activate p53 in AML with vary-
ing efficacy (Kojima et al., 2005; Long et al., 2010), underscoring
the need to further dissect the heterogeneity and oncogene-spe-
cificmechanisms. HDAC1, 2, 3, and Sirtuins are known tomodu-
late p53 activity by deacetylation (Juan et al., 2000; Luo et al.,
2000; Ito et al., 2002). We show that HDAC8 can deacetylate
p53 and modulate its activity, similar to other class I HDACs.
Inhibiting HDAC8 substantially enhances p53 activation and
diminishes AML cell survival under oncogenic or genotoxic
stress, supporting HDAC8 as a promising therapeutic target.
Most HDAC inhibitors including vorinostat, currently used or be-
ing tested in clinical trials, display relatively low activities against
HDAC8 (Khan et al., 2008). Our team has recently developed
ortho-aryl N-hydroxycinnamides including 22d (Huang et al.,
2012), with superior anti-HDAC8 selectivity and potency
compared to the hydroxamic acid inhibitor PCI-34051 previously
reported (Balasubramanian et al., 2008). All HDAC8i compounds
we tested showed similar effects as HDAC8 knockdown or dele-
tion. Compared to other class I-, III-, or broad-spectrum HDAC
inhibitors, 22d selectively enhanced Ac-p53 and the HDAC8-
specific substrate Ac-SMC3. Further, the sensitivity to 22d can
be modulated by genetically manipulating HDAC8 or p53 status.
These results indicate that a 22d regimen, at least at lower
doses, reactivates p53 through specific inhibition of HDAC8.
Inhibition of other HDAC members or other off-target effects is
possible at higher doses (e.g., >20 mM). Clearly, further develop-
ment and improvement of HDAC8i for pre-clinical and clinical
studies is warranted.
In conclusion, we demonstrate a mechanism whereby CM
aberrantly interacts with p53 and HDAC8, leading to deacetyla-
tion and inactivation of p53 by HDAC8. Our results indicate that
HDAC8 acts to promote CM-associated AML LSC transforma-
tion and maintenance. Remarkably, HDAC8i treatment restoresom vehicle (n = 5) or 22d treated (n = 4) mice (***p < 0.0001).
le (n = 5) or 22d treated (n = 4) BM (***p = 0.0006).
d (n = 4) BM (*p = 0.0159).
(n = 4) BM (**p = 0.0049).
c.
Figure 7. Propagation of Primary Inv(16)+ AML Is Diminished by In Vivo HDAC8i 22d Treatment
(A) Schematic illustration of the experimental design. The primary inv(16)+ AML cells from patient AML1070 (see Table S1) were depleted of T cells and
directly injected intrafemorally into irradiated (300 cGy) NSGS mice (1 3 106 cells/mouse). Human AML hCD45+ cells were selected from the leukemic BM
for transplantation (2 3 106 hCD45+ cells/mouse) into larger cohorts of NSGS mice. When the AML progression was evident, we began treatment with 22d
(50 mg/kg/dose) or vehicle twice daily for 2 weeks. The treated mice were then analyzed for AML burden and the BM cells were transplanted into secondary
recipients.
(B) Representative FACS plots showing gating and frequency of hCD45+ (left) and hCD45+/CD34+ (right) cells in BM of mice treated with vehicle (top) or 22d
(bottom) for 2 weeks.
(C) Frequency of hCD45+ AML cells in the PB of vehicle or 22d treated mice (n = 5) (p = 0.0159).
(legend continued on next page)
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p53 acetylation and activity, induces apoptosis, and abrogates
AML propagation and the leukemia-initiating activity of inv(16)+
LSCs. This study highlights HDAC8 as an attractive therapeutic
target and provides the rationale for designing HDAC8-directed




Mobilized PBSC were obtained from healthy donors and AML samples were
obtained from patients (Table S1) at City of Hope (COH). CD34+ cell isolation
was performed using MACS or CliniMACS (Miltenyi Biotech). Samples were
acquired with signed informed consent and approval by the COH Institutional
ReviewBoard, in accordancewith an assurance filedwith and approved by the
Department of Health and Human Services.
Mice
AllCbfb56M/+ (Kuo et al., 2006) andMx1-Cre (Ku¨hn et al., 1995) mice used were
backcrossed to C57BL/6 for more than ten generations. C57BL/6, Ai14 Cre
reporter, and NSGS mice were obtained from the Jackson Laboratory. To
induce CM, 6- to 8-week-old Mx1-Cre/Cbfb56M/+ mice were intraperitoneally
(i.p.) injected with 250 mg of pIpC (InvivoGen) every other day for 14 days
(seven doses). Similarly treated Cbfb56M/+ littermates were used as control.
Pre-leukemic cells were isolated 2 weeks after the last dose of pIpC. AML
transplant was performed via tail vein injection into sublethally irradiated (6.5
Gy) 6- to 8-week-old congenic C57BL/6 mice (CD45.1+). Human AML cells
were depleted of T cells using MACS (Miltenyi Biotech) and transplanted
into irradiated (300 cGy) NSGS mice via intrafemoral injection. In vivo 22d/
vehicle treatment was performed by i.p. injection (50 mg/kg/dose) twice a
day. All mice were maintained in an Association for Assessment and Accred-
itation of Laboratory Animal Care (AAALAC)-accredited animal facility and all
procedures were performed in accordance with federal and state government
guidelines and established institutional guidelines and protocols approved by
the Institutional Animal Care and Use Committee at the Beckman Research
Institute of COH.
IP and Western Blotting
Cells were lysed in radioimmunoprecipitation assay buffer (RIPA) buffer
containing a protease inhibitor cocktail (Roche) and MG132. Antibodies
used for IP were conjugated with protein A/G beads using the antibody
cross-linking kit (Pierce Biotechnology) following the manufacturer’s instruc-
tions. For western blot analysis, proteins were resolved using 10% SDS-
PAGE. The antibodies used included anti-FLAG (M2; Sigma), anti-HDAC8
(H145, E5; Santa Cruz), anti-CBFb (141,4,1; Santa Cruz), anti-p53 (DO-1,
1C12), anti-Ac-p53 (K379) (Cell Signaling), anti-SMC3 (Bethyl Laboratories),
anti-Ac-SMC3 (MBL International), and anti-b-actin (Sigma). Horseradish
peroxidase-conjugated anti-rabbit or anti-mouse secondary antibodies
(Jackson ImmunoResearch) were used, followed by detection using the
SuperFemto kit (Pierce Biotechnology).
Statistics
Statistical analyses were performed with Student’s t test or ANOVA for NL
distributions. Mann-Whitney U tests were used when the criteria for a NL
distribution were not satisfied. A p value less than 0.05 was considered statis-
tically significant (*p < 0.05; **p < 0.01; and ***p < 0.001).(D) Frequency of hCD45+ AML cells in the BM of vehicle or 22d treated mice (n =
(E) Frequency of hCD45+/CD34+ AML cells in the BM of vehicle or 22d treated m
(F) The spleen weight of mice treated with vehicle (n = 5) or 22d (n = 5) (*p = 0.01
(G) Representative FACS plots of hCD45+/CD34+ AML cell frequency in BM of v
(H) Frequency of hCD45+ AML cells in BM of vehicle or 22d treated secondary tr
(I) Frequency of hCD45+/CD34+ AML cells in BM of vehicle or 22d treated secon
(J) Frequency of immunophenotypic populations within hCD45+ cells in BM of ve
(K) Survival curve of second transplant recipients of vehicle (n = 4) or 22d treated
See also Figure S6.
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